enGene Holdings (ENGNW) shares Q3 2025 results in 8-K filing

Rhea-AI Filing Summary

enGene Holdings Inc., a British Columbia company listed on The Nasdaq Stock Market LLC, furnished an update on its recent performance. The company announced its financial results for the third fiscal quarter ended July 31, 2025, and provided these details in a press release.

The press release, dated September 11, 2025, is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Securities Exchange Act of 1934, meaning it is not subject to certain liability provisions or automatically incorporated into other SEC filings. The report is signed by Chief Executive Officer and President Ronald H. W. Cooper.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001980845false00-000000000019808452025-09-112025-09-110001980845us-gaap:CommonStockMember2025-09-112025-09-110001980845us-gaap:WarrantMember2025-09-112025-09-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

enGene Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia			001-41854	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4868 Rue Levy, Suite 220
Saint-Laurent, Quebec, Canada				H4R 2P1
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (514) 332-4888

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		ENGN		The Nasdaq Stock Market LLC
Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Common Share		ENGNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On September 11, 2025, enGene Holdings Inc. (the "Company") announced its financial results for the third financial quarter ended July 31, 2025. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description of Exhibits
99.1		Press Release dated September 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ENGENE HOLDINGS INC.
Date:	September 11, 2025	By:	/s/ Ronald H. W. Cooper
			Name: Ronald H. W. Cooper Title: Chief Executive Officer and President

FAQ

What did enGene Holdings Inc. (ENGNW) disclose in this 8-K?

enGene Holdings Inc. furnished an 8-K stating that it announced its financial results for the third fiscal quarter ended July 31, 2025, via a press release attached as Exhibit 99.1.

Which period do the latest enGene (ENGNW) financial results cover?

The company’s latest announced financial results cover the third financial quarter ended July 31, 2025.

Where can investors find the detailed Q3 2025 results for enGene Holdings?

Detailed Q3 2025 results are contained in the press release dated September 11, 2025, which is included as Exhibit 99.1 to the 8-K.

Are enGene’s Q3 2025 results in this 8-K considered filed with the SEC?

The company states the information in this 8-K, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not automatically incorporated into other filings.

On which exchange are enGene Holdings Inc. securities listed?

enGene Holdings Inc.’s Common Shares (ENGN) and warrants (ENGNW) are listed on The Nasdaq Stock Market LLC.

Who signed the enGene Holdings Inc. Q3 2025 8-K?

The 8-K was signed on behalf of enGene Holdings Inc. by Ronald H. W. Cooper, the company’s Chief Executive Officer and President.